$NTLA 8-K SEC Filings

Filed On	Filing
08 Sep 2026	8-K: Regulation FD Disclosure; Other Events Intellia Therapeutics Announces FDA Acceptance of Biologics License Application with Priority Review for Lonvoguran Ziclumeran (Lonvo-z) for Hereditary Angioedema (HAE)
04 Sep 2026	8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +1 more
06 Aug 2026	8-K: Results of Operations and Financial Condition
15 Jun 2026	8-K: Regulation FD Disclosure; Other Events
10 Jun 2026	8-K: Submission of Matters to a Vote of Security Holders
11 May 2026	8-K: Results of Operations and Financial Condition
30 Apr 2026	8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition
27 Apr 2026	8-K: Regulation FD Disclosure; Other Events
10 Apr 2026	8-K: Amendments to Articles/Bylaws; Change in Fiscal Year
02 Mar 2026	8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure +1 more
26 Feb 2026	8-K: Results of Operations and Financial Condition
27 Jan 2026	8-K: Regulation FD Disclosure; Other Events
09 Jan 2026	8-K: Regulation FD Disclosure; Other Events
10 Nov 2025	8-K: Regulation FD Disclosure; Other Events
06 Nov 2025	8-K: Results of Operations and Financial Condition
29 Oct 2025	8-K: Other Events
27 Oct 2025	8-K: Regulation FD Disclosure; Other Events
25 Sep 2025	8-K: Regulation FD Disclosure; Other Events
07 Aug 2025	8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation
16 Jun 2025	8-K: Regulation FD Disclosure; Other Events

Comments